晚期原发性肝癌的肝动脉灌注化疗

摘要/Abstract

摘要：

原发性肝癌（Hepatocellular carcinoma, HCC）是最常见的恶性肿瘤之一。手术切除、肝移植、消融等根治方法仅适合于早期患者。不幸的是,绝大多数患者在确诊时已经是中晚期,不适合上述根治性方法。依据现有的国际指南,索拉非尼是晚期HCC唯一的标准治疗方法,但是,索拉非尼的疗效并不理想,且临床实践中部分患者不适合分子靶向药物治疗。目前对于索拉非尼治疗失败的晚期HCC也缺乏行之有效的治疗手段。因此,需要探索晚期HCC的其他有效治疗方法。在众多的治疗方法中,肝动脉灌注化疗（Hepatic arterial infusion chemotherapy, HAIC）是一种少有的能提高疗效的方法。HAIC能将药物直接输送至肝脏肿瘤供血血管内,通过肝脏的首过效应降低化疗药物的全身毒性。尽管许多研究证实HAIC有效,但是,由于缺乏可信的大样本随机对照研究,HAIC治疗晚期HACC的疗效仍然受到质疑。本文主要介绍HAIC在晚期HCC治疗中的应用。

关键词: 原发性肝癌（HCC）, 肝动脉灌注化疗（HAIC）, 晚期, 临床研究

郭建海, 朱旭. 晚期原发性肝癌的肝动脉灌注化疗[J]. 肝癌电子杂志, 2019, 6(4): 20-23.

参考文献 34

[1]	Fitzmaurice C , et al. Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the Global Burden of Disease study[J]. JAMA Oncol, 2018,4(11):1553-1568.
[2]	European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer; EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2012,56(4):908-943.
[3]	Parkin DM, Bray F, Ferlay J , et al. Global cancer statistics, 2002[J]. CA Cancer J Clin, 2005,55:74-108.
[4]	Tanaka M, Katayama F, Kato H , et al. Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures[J]. J Epidemiol, 2011,21:401-416.
[5]	Llovet JM, Ricci S, Mazzaferro V , et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008,359:378-390.
[6]	Cheng AL, Guan Z, Chen Z , et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial[J]. Eur J Cancer, 2012,48:1452-1465.
[7]	Park JY, Ahn SH, Yoon YJ , et al. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma[J]. Cancer, 2007,110:129-137.
[8]	Ishikawa T, Imai M, Kamimura H , et al. Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a pilot study[J]. World J Gastroenterol, 2007,13:5465-5470.
[9]	Song MJ, Bae SH . Newer treatments for advanced hepatocellular carcinoma[J]. Korean J Intern Med, 2014,29:149-155.
[10]	Song MJ . Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma[J]. World J Gastroenterol, 2015,21:3843-3849.
[11]	Ando E, Tanaka M, Yamashita F , et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases[J]. Cancer, 2002,95:588-595.
[12]	Ueshima K, Kudo M, Takita M , et al. Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma[J]. Oncology, 2010,78:148-153.
[13]	Yamashita T, Arai K, Sunagozaka H , et al. Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma[J]. Oncology, 2011,81:281-290.
[14]	Obi S, Yoshida H, Toune R , et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion[J]. Cancer, 2006,106:1990-1997.
[15]	Yano H, Iemura A, Haramaki M , et al. Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines[J]. Hepatology, 1999,29:1708-1717.
[16]	Hamada A, Yamakado K, Nakatsuka A , et al. Hepatic arterial infusion chemotherapy with use of an implanted port system in patients with advanced hepatocellular carcinoma: prognostic factors[J]. J Vasc Interv Radiol, 2004,15:835-841.
[17]	Lin CP, Yu HC, Cheng JS , et al. Clinical effects of intra-arterial infusion chemotherapy with cisplatin, mitomycin C, leucovorin and 5-flourouracil for unresectable advanced hepatocellular carcinoma[J]. J Chin Med Assoc, 2004,67:602-610.
[18]	Hwang JY, Jang BK, Kwon KM , et al. Efficacy of hepatic arterial infusion therapy for advanced hepatocellular carcinoma using 5-fluorouracil, epirubicin and mitomycin-C[J]. Korean J Gastroenterol, 2005,45:118-124.
[19]	Woo HY, Bae SH, Park JY , et al. A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma[J]. Cancer Chemother Pharmacol, 2010,65:373-382.
[20]	Kim BK, Park JY, Choi HJ , et al. Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2011,137:659-667.
[21]	Nagano H, Kobayashi S, Marubashi S , et al. Combined IFN-α and 5-FU treatment as a postoperative adjuvant following surgery for hepatocellular carcinoma with portal venous tumor thrombus[J]. Exp Ther Med, 2013,5:3-10.
[22]	Nitta H, Beppu T, Imai K , et al. Adjuvant hepatic arterial infusion chemotherapy after hepatic resection of hepatocellular carcinoma with macroscopic vascular invasion[J]. World J Surg, 2013,37:1034-1042.
[23]	Kumamoto T, Tanaka K, Matsuo K , et al. Adjuvant hepatic arterial infusion chemotherapy with 5-Fluorouracil and interferon after curative resection of hepatocellular carcinoma: a preliminary report[J]. Anticancer Res, 2013,33:5585-5590.
[24]	Nishikawa H, Osaki Y, Kita R , et al. Transcatheter arterial infusion chemotherapy prior to radiofrequency thermal ablation for single hepatocellular carcinoma reduces the risk of intrahepatic distant recurrence[J]. Int J Oncol, 2012,41:903-909.
[25]	Ishikawa T, Kubota T, Abe S , et al. Hepatic arterial infusion chemotherapy with cisplatin before radical local treatment of early hepatocellular carcinoma (JIS score 0/1) improves survival[J]. Ann Oncol, 2014,25:1379-1384.
[26]	Sumie S, Yamashita F, Ando E , et al. Interventional radiology for advanced hepatocellular carcinoma: comparison of hepatic artery infusion chemotherapy and transcatheter arterial lipiodol chemoembolization[J]. AJR Am J Roentgenol, 2003,181:1327-1334.
[27]	Kim HY, Kim JD, Bae SH , et al. A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma[J]. Korean J Hepatol, 2010,16:355-361.
[28]	Nouso K, Miyahara K, Uchida D , et al. Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan[J]. Br J Cancer, 2013,109:1904-1907.
[29]	Tsai WL, Lai KH, Liang HL , et al. Hepatic arterial infusion chemotherapy for patients with huge unresectable hepatocellular carcinoma[J]. PLoS ONE, 2014, 13; 9:e92784.
[30]	Hiramine Y, Uto H, Imamura Y , et al. Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: A comparative study[J]. Exp Ther Med, 2011,2:433-441.
[31]	Song DS, Song MJ, Bae SH , et al. A comparative study between sorafenib and hepatic arterial infusion chemotherapy 31 for advanced hepatocellular carcinoma with portal vein tumor thrombosis[J]. J Gastroenterol 2015,50:445-454.
[32]	MinKe He, QiJiong Li, RuHai Zou, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion a randomized clinical trial. JAMA Oncol. 2019,5(7):953-960.
[33]	Sakon M, Nagano H, Dono K , et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches[J]. Cancer, 2002,94:435-442.
[34]	Ishikawa M, Kakizawa H, Hieda M , et al. Long-term outcomes of hepatic arterial port implantation using a coaxial microcatheter system in 176 patients with hepatocellular carcinoma[J]. Hiroshima J Med Sci, 2012,61:7-13.

晚期原发性肝癌的肝动脉灌注化疗

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 34

相关文章 0

编辑推荐

Metrics

本文评价